NCT00128661View on ClinicalTrials.gov

Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants

PHASE3CompletedINTERVENTIONAL
Enrollment

7,466

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions
Cervical CancerPrecancerous Condition
Interventions
BIOLOGICAL

human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine

Three doses of Cervarix vaccine administered on a 0, 1, 6-month schedule

BIOLOGICAL

hepatitis A inactivated virus vaccine

Three doses of Havrix vaccine administered on a 0, 1, 6-month schedule

Trial Locations (1)

Unknown

Proyecto Epidemiologico Guanacaste, Liberia

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00128661 - Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants | Biotech Hunter | Biotech Hunter